Clearpoint Neuro Inc CLPT.OQ CLPT.O is expected to show a rise in quarterly revenue when it reports results on May 13 for the period ending March 31 2025
The Solana Beach California-based company is expected to report a 7.3% increase in revenue to $8.2 million from $7.64 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Clearpoint Neuro Inc is for a loss of 16 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Clearpoint Neuro Inc is $28.00, above its last closing price of $14.25.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.19 | -0.16 | -0.20 | Missed | -22.5 |
Sep. 30 2024 | -0.19 | -0.17 | -0.18 | Missed | -3.8 |
Jun. 30 2024 | -0.19 | -0.20 | -0.16 | Beat | 18.6 |
Mar. 31 2024 | -0.18 | -0.19 | -0.16 | Beat | 15.8 |
Dec. 31 2023 | -0.18 | -0.20 | -0.19 | Beat | 6.6 |
Sep. 30 2023 | -0.25 | -0.25 | -0.20 | Beat | 20 |
Jun. 30 2023 | -0.19 | -0.19 | -0.29 | Missed | -52.6 |
Mar. 31 2023 | -0.18 | -0.18 | -0.23 | Missed | -24.3 |
This summary was machine generated May 9 at 21:31 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)